Background: There are limited data to determine the impact of subarachnoid blockade with local anesthetics on perioperative pulmonary function. The effects of local anesthetics used in spinal anesthesia are very important in terms of respiratory function in patients with chronic obstructive pulmonary disease (COPD).
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is the most common pulmonary disorder encountered in anesthetic practice. 1, 2 Most patients are only slightly symptomatic or are asymptomatic. Although regional anesthesia is often preferred to general anesthesia, high spinal or epidural anesthesia may reduce lung volumes, restrain the use of accessory respiratory muscles, and produce an ineffective cough, which leads to dyspnea with retention of secretions. 1, 2 Previous studies have demonstrated the effects of levobupivacaine and racemic bupivacaine on patients undergoing urologic surgery. 3, 4 However, the effects of intrathecal bupivacaine and levobupivacaine on respiratory function of patients with COPD undergoing elective transurethral surgery have not been studied. Levobupivacaine, the S-(-)-isomer of bupivacaine, is a long-acting local anesthetic that shows less toxicity in the cardiac and central nervous systems compared with bupivacaine. 5, 6 In this study, our aim was to evaluate the effect of spinal anesthesia with 0.5% hyperbaric bupivacaine versus 0.5% isobaric levobupivacaine on the pulmonary function of patients with COPD undergoing elective transurethral surgery.
PATIENTS AND METHODS
This single-center, prospective, randomized, double-blind study was conducted at the Trakya University Medical Faculty. After obtaining approval from the local ethics committee and written informed consent, 53 male patients aged 40 to 80 years with moderate COPD and American Society of Anesthesiologists (ASA) II-III physical status who were scheduled for elective transurethral surgery under spinal anesthesia were enrolled in the study.
Patients were classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. 7 All patients were in GOLD stage II with moderate airflow obstruction, defined as forced expiratory volume in 1 second (FEV 1 ) of 50% to 80%, and were current or ex-smokers with a smoking history of Ͼ10 packs/year (FEV 1 /forced vital capacity [FVC] ratio Ͻ70%).
Exclusion criteria were coagulation disturbances, neuromuscular diseases, morbid obesity, hypersensitivity to amide local anesthetics, infection at the injection site, bronchial asthma requiring regular therapy, cardiac problems associated with dyspnea, and severe psychiatric disorders.
No patients received premedication. On arrival in the anesthetic room, a 16-gauge intravenous cannula was inserted and 500-mL lactated Ringer solution was infused for 20 minutes. Monitored parameters were 3-lead electrocardiogram, heart rate (beats/min), noninvasive blood pressure (mm Hg), and pulse oximetry (SpO 2 [%] ).
The random assignments of patients were prepared outside the study center and inserted in opaque, sealed, sequentially numbered envelopes. Patients in group B (n ϭ 25) received 3 mL of hyperbaric 0.5% bupivacaine*; patients in group L (n ϭ 25) received 3 mL of isobaric levobupivacaine.
† Hyperbaric 0.5% bupivacaine or isobaric levobupivacaine was administered in a randomized, double-blind fashion after local infiltration with 2 mL of lidocaine 2%. Both drugs were aseptically and intrathecally administered to patients in a sitting position, through a 25-gauge Quincke point spinal needle by a midline approach between the L3-L4 intervertebral space. After the free flow of cerebrospinal fluid was verified, local anesthetic was given over 15 seconds, without aspiration. The anesthesiologist performing the spinal anesthesia was not aware of group allocation. A separate independent anesthesiologist prepared all local anesthetic solutions. Immediately after administration, the patients were turned to a supine position. During the procedure, supplementary oxygen at 2 L/min was given via face mask.
Sensory and motor blocks were assessed by the pinprick test (1 ϭ hypoalgesia; 2 ϭ analgesia; 3 ϭ analgesia plus hypoesthesia; 4ϭ anesthesia) and by a modified Bromage scale (0 ϭ no motor block; 1 ϭ ability to move knees only, inability to raise extended legs; 2 ϭ inability to flex knees; 3 ϭ fully motor block), respectively. The anesthetist performing the pinprick test and modified Bromage scale was blinded to group allocation. Sensory and motor onset time, maximal spread of sensory block, duration of sensory and motor block, and time to L2 segment regression (time to lumbar spine 2 segment regression of spinal anesthesia) were recorded.
When the sensory block reached the T10 level (Thoracic dermatome), patients were placed in the lithotomy position for surgery and the surgical procedure was started. Intraoperatively, the patients received 10 mL/kg/h of lactated Ringer solution.
Anesthetic and vital parameters were recorded every 2 minutes for the first 30 minutes after the intrathecal injection, every 5 minutes during the surgical procedure, and every hour postoperatively until motility and sensitivity returned to basal conditions.
Mean arterial pressure Ͻ60 mm Hg, or a decrease Ͼ25% from baseline, was defined as hypotension and treated with a 5-mg ephedrine bolus; a heart rate Ͻ50 beats/min was defined as bradycardia and treated with 0.5 mg of atropine. A decrease in SpO 2 to Ͻ93% was defined as hypoxia and treated with supplemental assisted ventilation by a face mask.
For spirometric measurements, the Spiro Analyzer ST-90 (Fukuda Sangyo, Tokyo, Japan) was used. Spirometry was standardized with each patient in the supine position on the bed or operating table with a 30-degree head-up position. The anesthetist performing spirometry monitoring and evaluating was blinded to group allocation. After an exact demonstration of the correct usage during the pre-anesthetic visit, we performed spirometry and the measurement was determined as the baseline. The FVC, FEV 1 , peak expiratory flow rate (PEFR), vital capacity (VC), and FEV 1 /FVC *Trademark: Marcaine ® Heavy 0.5% (AstraZeneca, Södertälje, Sweden). † Trademark: Chirocaine ® (Abbott Scandinavia AB, Solna, Sweden).
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ratio were calculated using spirometry at the operating room 10 and 30 minutes after spinal anesthesia and 30 minutes after the completion of the operation. At assessment, spirometry was performed at least 3 times to meet the criteria of the European Respiratory Society, and the best measurement was recorded. 8 Arterial blood was usually obtained by percutaneous needle puncture of a palpable artery. Primarily radial arteries were used. We measured arterial blood gas on arrival at the operating room and 30 minutes after the end of the operation (during 30 minutes under supplemental oxygen) (ABL 800 Series; Radiometer America, Westlake, Ohio).
Statistical Analysis
An unpaired t test was applied to compare the data between groups; a paired t test was applied to compare data within the groups. Normal distribution of data was tested via 1 sample Kolmogorov-Smirnov test. P Ͻ 0.05 was considered to be significant. For calculations, the Statistica 7.1 software program was used (StatSoft, Tulsa, Oklahoma).
RESULTS
Of 53 patients assessed for eligibility, 3 patients were excluded because of failed spinal anesthesia. Fifty patients were followed according to protocol. Twenty-five patients were included in each of the 2 groups (Figure) . The 2 groups have homogeneous results relating to age, weight, height, body mass index, ASA physical status, and duration of surgery ( Table I) .
There were no differences in mean arterial pressure, heart rate, and SpO 2 between the groups. In all patients, SpO 2 values remained higher than 97% during the procedure. No patients required sedation.
There were no significant differences between groups regarding sensory and motor onset times, maximal spread of sensory block, duration of sensory block and motor block, and time to L2 segment regression of spinal anesthesia (Table II ; P ϭ 0.081, P ϭ 0.071, P ‫؍‬ 0.301, P ϭ 0.068, P ϭ 0.349, and P ϭ 0.069, respectively). The block level at 15 minutes after the subarachnoid injection was significantly higher in patients who received bupivacaine than in patients who received levobupivacaine (P ϭ 0.011). No adverse effects, such as hypotension, bradycardia, nausea, respiratory depression, or weakness, were observed.
FVC, FEV 1 , VC, and FEV 1 /FVC ratio did not differ significantly from baseline to 10 minutes, 30 minutes, and the postoperative period in either group. Patients in the bupivacaine group showed a significant decrease in intraoperative PEFR at 30 minutes compared with baseline, which was a result not seen in the levobupivacaine group (Table III ; P ϭ 0.036 and P ϭ 0.282, respectively). The values of FVC, FEV 1 , PEFR, VC, and FEV 1 /FVC ratio showed no significant differences between the groups in the intraoperative (10 and 30 minutes) and postoperative periods (Table III) .
There were no differences in intraoperative and postoperative arterial blood gas results for the values of potential hydrogen, partial pressure of oxygen, partial pressure of carbon dioxide, bicarbonate, base excess, and SpO 2 between the two groups.
Postoperative arterial blood gas results of potential hydrogen, partial pressure of oxygen, partial pressure of carbon dioxide, bicarbonate, base excess, and SpO 2 did not differ from the intraoperative values in either group.
DISCUSSION
In this study the intrathecal administration of 0.5% hyperbaric bupivacaine or 0.5% isobaric levobupivacaine to 2 separate but homogeneous groups of patients with COPD undergoing elective transurethral surgery showed no significant differences with regard to pulmonary function. However, hyperbaric bupivacaine decreased intraoperative PEFR at 30 minutes from baseline.
Patients with severe chronic lung insufficiency may depend on intercostal and abdominal muscles to actively inspire or exhale. Furthermore, clearing of secretions and effective coughing require intercostal and abdominal muscles for expirations. 2 These muscles would be damaged by the high levels of neuraxial block with local anesthetics. Thus, Figure. Disposition of patients randomly assigned to receive hyperbaric bupivacaine (n ‫؍‬ 25) or isobaric levobupivacaine (n ‫؍‬ 25) in this study to evaluate the effects of these agents on pulmonary function in patients with chronic obstructive pulmonary disease undergoing urologic surgery.
neuraxial blocks with local anesthetics should be used with caution in patients with COPD. A regional technique may not be the best choice in patients with severe lung disease for surgical procedures above the umbilicus. 9,10 Therefore, we performed spinal anesthesia for transurethral surgery using bupivacaine or levobupivacaine.
PEFR is a good indicator of cough effectiveness. The abdominal muscles are important in producing an effective cough because they increase intra-abdominal pressure and intrapulmonary pressure.
11,12 Therefore, we believe that the subarachnoid blockade with local anesthetic used in our study decreased PEFR by inducing motor blockade of the abdominal wall muscles. Because the hyperbaric bupivacaine provided a higher level block compared with isobaric levobupivacaine, patients who received bupivacaine showed a significant decrease in intraoperative PEFR at 30 minutes compared with baseline. However, there were no significant differences between the groups regarding PEFR. The present study indicated that from the standpoint of respiration, hyperbaric bupivacaine and isobaric levobupivacaine in spinal anesthesia are both well tolerated by patients with COPD. *No statistically significant differences were obtained in any of the parameters among groups (P Ͼ 0.05). *Differences were significant in group B at 30 minutes for PEFR.
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A subarachnoid blockade with local anesthetics causes a decrease in diaphragmatic strain due to the block of the motor nerve fibers to the abdominal wall muscles. Therefore, the diaphragm moves more easily during inspiration. This mechanism could make the inspiratory lung volume increase and prevent spirometric parameters from decreasing. 11 Therefore, subarachnoid blockade with hyperbaric bupivacaine or isobaric levobupivacaine induced almost no changes in FVC, FEV 1 , VC, and FEV 1 / FVC ratio in our study.
Levobupivacaine recently has been introduced into clinical practice because of its lower toxic effects on the heart and central nervous system. 5 Therefore, levobupivacaine may be a good alternative for spinal anesthesia during transurethral surgery in critically ill patients. However, previous studies did not include data regarding the spread, sensory block, and motor block of spinal anesthesia with isobaric and hyperbaric local anesthetic solutions and the effect of pulmonary function in patients with COPD. The addition of dextrose to local anesthetics increases the density and obtains a high sensory block. 13 The gravity of the injection into the subarachnoid space is known to influence the spread of subarachnoid blockade.
14 Based on information from the producers, the gravity of hyperbaric bupivacaine and isobaric levobupivacaine were 1.028 and 1.004, respectively. The hyperbaric bupivacaine (addition of dextrose) provided a higher level block, compared with the isobaric levobupivacaine, without leading to deterioration in respiratory function and arterial blood gas tests in our study.
Our study was limited by several factors, particularly sample size. An increase in the sample size may change the results. Similarly, if the sample size were larger, significant differences in the results might be determined, so the conclusions might be stricter. Another limitation is that the use of other local anesthetic drugs may affect the study results.
CONCLUSIONS
Hyperbaric bupivacaine can cause a decrease in intraoperative PEFR compared with baseline because of higher level block. The effects of hyperbaric bupivacaine and isobaric levobupivacaine on pulmonary function in patients with COPD, however, show equally effective potencies for spinal anesthesia. This hypothesis awaits further studies to establish its clinical significance.
